BioPharma and Health Reform: The Good, the Bad, and the Just Plain Ugly
This article was originally published in RPM Report
Executive Summary
While the prospects for major health reform are unclear, there is more clarity to what biopharma has at stake: A lot. In this issue, The RPM Report presents a guide to the upsides and downsides for the biopharma industry of some of the major issues in health reform and some handicapping of the likelihood of each.